Cantor Fitzgerald Sticks to Its Buy Rating for Paratek Pharmaceuticals

By Jason Carr

Patek Pharma logo In a report released today, Chiara Russo from Cantor Fitzgerald reiterated a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK), with a price target of $33. The company’s shares opened today at $20.35.

Russo said:

“PRTK presented 10 posters at this year’s ASM Microbe, though data around the Phase 1 UTI trial and gut microbiota piqued our attention.”

According to, Russo is a 2-star analyst with an average return of 0.7% and a 38.8% success rate. Russo covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics Inc, Flexion Therapeutics, and Cidara Therapeutics.

Paratek Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $35.20.

Based on Paratek Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $18K and GAAP net loss of $27.67 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $31.27 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.